IMMEDICA PHARMA
PharmaIMMEDICA PHARMA is a pharmaceutical company focused on Neurology. Key products include ZTALMY.
FDA Novel Drug Designations
(2022)See 1 novel approval →
IMMEDICA PHARMA's Key Drugs
IMMEDICA PHARMA's core commercial portfolio centers on ZTALMY, spanning Neurology — its most strategically important drugs approved in the last 15 years.
IMMEDICA PHARMA's Recent FDA Approvals
New NDA/BLA approvals for IMMEDICA PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
IMMEDICA PHARMA's Therapeutic Areas
IMMEDICA PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMMEDICA PHARMA's Top Competitors
IMMEDICA PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMMEDICA PHARMA Pipeline Snapshot
Active clinical trials for IMMEDICA PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZTALMY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-03-18
- Latest
- 2025-10-16
- Applications
- 1